A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Conditions: Rhabdoid Tumors; INI1-negative Tumors; Synovial Sarcoma; Malignant Rhabdoid Tumor of OvaryIntervention: Drug: TazemetostatSponsor: Epizyme, Inc.Not yet recruiting - verified November 2015

http://clinicaltrials.gov/ct2/show/NCT02601937?lup_s=10%2F18%2F2015&lup_d=30

Source: ClinicalTrials.gov - October 21, 2015 Category: Research Source Type: clinical trials